- Home
- DCI vs ROIV Comparison
DCI vs ROIV Comparison
Compare DCI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCI
- ROIV
- Stock Information
- Founded
- DCI 1915
- ROIV 2014
- Country
- DCI United States
- ROIV United Kingdom
- Employees
- DCI N/A
- ROIV N/A
- Industry
- DCI Pollution Control Equipment
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- DCI Industrials
- ROIV Health Care
- Exchange
- DCI Nasdaq
- ROIV Nasdaq
- Market Cap
- DCI 9.7B
- ROIV 8.6B
- IPO Year
- DCI 1987
- ROIV N/A
- Fundamental
- Price
- DCI $84.25
- ROIV $19.99
- Analyst Decision
- DCI Hold
- ROIV Strong Buy
- Analyst Count
- DCI 3
- ROIV 8
- Target Price
- DCI $80.33
- ROIV $21.06
- AVG Volume (30 Days)
- DCI 497.5K
- ROIV 8.0M
- Earning Date
- DCI 12-02-2025
- ROIV 11-10-2025
- Dividend Yield
- DCI 1.42%
- ROIV N/A
- EPS Growth
- DCI N/A
- ROIV N/A
- EPS
- DCI 3.05
- ROIV N/A
- Revenue
- DCI $3,690,900,000.00
- ROIV $23,233,000.00
- Revenue This Year
- DCI $4.36
- ROIV N/A
- Revenue Next Year
- DCI $4.52
- ROIV $320.50
- P/E Ratio
- DCI $27.62
- ROIV N/A
- Revenue Growth
- DCI 2.92
- ROIV N/A
- 52 Week Low
- DCI $57.45
- ROIV $8.73
- 52 Week High
- DCI $84.88
- ROIV $20.09
- Technical
- Relative Strength Index (RSI)
- DCI 61.46
- ROIV 86.17
- Support Level
- DCI $82.59
- ROIV $17.89
- Resistance Level
- DCI $84.88
- ROIV $18.96
- Average True Range (ATR)
- DCI 1.40
- ROIV 0.59
- MACD
- DCI -0.00
- ROIV 0.14
- Stochastic Oscillator
- DCI 87.15
- ROIV 97.67
About DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.7 billion in revenue in its fiscal 2025.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.